Trial Profile
A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily Via a Dry Powder Inhaler Compared With Placebo in Subjects of Asian Ancestry With Chronic Obstructive Pulmonary Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 Jun 2011 New trial record